Trial Profile

Phase III Study of YM178 - A Placebo-controlled, Double-blind, Group Comparison Study in Patients With Overactive Bladder

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Mirabegron (Primary) ; Tolterodine
Indications Overactive bladder
Focus Registrational; Therapeutic Use
Sponsors Astellas Pharma

Most Recent Events

01 Jan 2022 Results of post-hoc analysis using pooled data from phase IIb and a phase III studies (NCT00527033 & NCT00966004) assessing efficacy of mirabegron were published in the International Journal of Urology.
28 Jan 2014 Results published in the BJU International.
18 Jun 2010 Primary endpoint 'Micturition rate' has been met according to an Astellas Pharma media release.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com